FDA panel votes to loosen restrictions for controversial peptides - BBC

What the report says

BBC News reports that a US Food and Drug Administration advisory panel has narrowly voted to ease restrictions on several controversial peptides, including BPC-157, TB-500 and KPV. The decision is a significant step toward allowing specialised compounding pharmacies to make the substances available by prescription, though the FDA is not required to accept the panel’s advice. The panel was continuing deliberations on other peptides on Friday, according to the report.

Peptides are short chains of amino acids that occur naturally in the body and are used in some established medicines, including treatments for diabetes. But the BBC says injectable peptides promoted online have grown popular in wellness and fitness circles, especially after the rise of GLP-1 weight-loss drugs. Influencers have marketed them for unproven purposes such as muscle growth, skin improvement, healing and “biohacking,” despite warnings from health experts that human research remains limited and long-term effects are uncertain.

BPC-157, described as one of the most visible peptides in the trend, has been promoted for gut health, inflammation and tissue repair, and has been studied in animals for possible muscle-healing effects. The US Anti-Doping Agency has warned that there is no known safe dose for human treatment, and the World Anti-Doping Agency bans it in sport. KPV is similarly promoted for gut, skin and immune-related benefits, but is not approved for human use.

The vote is also politically notable. BBC News says Health Secretary Robert F Kennedy has called himself a supporter of the drugs and pledged to roll back restrictions imposed under the Biden administration. One panel member cited lack of efficacy data and safety concerns in voting against BPC-157, while supporters reportedly invoked medical freedom and broader patient access.